| Name | Title | Contact Details |
|---|
Pioneer Surgical is a leading innovator in the design and manufacture of spinal and orthopedic implants and instruments.
Inner Dimension TV is a monthly subscription platform full of high-quality cinematic yoga and meditation classes. Start your 10-day free trial today.
Built around a portfolio of recognized brands, Golden Leaf Holdings Incorporate is one of the largest cannabis oil and solution providers in North America. The Company leverages a strong management team with cannabis and food industry experience to complement its expertise in the extracting, refining and selling of cannabis oil, edibles and flower products. The Company has developed a strong consumer brand portfolio (“Golden Brands”) that includes the Golden, Proper, Chalice Farms, Liberty Reach and Jackpot Seaweed brands. In addition to leading branded products, Golden Leaf also maintains a foothold in the Oregon retail dispensary market with its award-winning chain of Chalice Farms retail stores.
Cottingham & Butler is the 35th largest insurance broker in the U.S. with over 600 employees dedicated to providing our clients with advice and insurance products to manage the risks they face. Our business model allows for assisting companies in three primary areas: 1. Transportation risks for large and small fleet operations 2. Risk management for manufacturing, construction, distribution and service industry clients. This area grew by over 40% in the last year. 3. Employee Benefits providing fully insured and self-funding options to cleints. Our benefits programs are fully integrated with clients to include FMLA, Health Risk Assessments and Short Term Disability services plus Executive Life and Disability services.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.